Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old (LAM-SA 2007)
Randomized Prospective Study of Adding Lomustine to Idarubicin and Cytarabine for Induction and Post-remission Chemotherapy in Older Patients With Acute Myeloid Leukaemia, and Feasibility of Allogeneic Transplantation for Patients From 60 to 65 Years Old
Sponsor: University Hospital, Bordeaux
Listed as NCT00590837, this PHASE3 trial focuses on Acute Myeloid Leukemia and remains completed. Sponsored by University Hospital, Bordeaux, it has been updated 6 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Feb 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital, Bordeaux
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Angers, France , Annecy, France , Argenteuil, France , Avignon, France , Bayonne, France , Besançon, France , Blois, France , Bordeaux - Pessac, France , Boulogne-sur-Mer, France and 22 more locations